10.1 C
Imphal
Friday, January 28, 2022
No menu items!

Pfizer says new trials prove high efficacy of Covid-19 oral treatment

The company said it analyzed results from 2,246 high-risk adult patients that received its oral antiviral candidate PAXLOVID in comparison to those that took a placebo.

Must Read

New York: A new stage of trials proved the high efficacy of Pfizer’s oral antiviral treatment against Covid-19 by reducing risk of hospitalization or death by 89 per cent, the company announced on Tuesday.

The company said it analyzed results from 2,246 high-risk adult patients that received its oral antiviral candidate PAXLOVID in comparison to those that took a placebo.

- Advertisement -

“These results were consistent with the interim analysis announced in November 2021, showing PAXLOVID significantly reduced the risk of hospitalization or death for any cause by 89 per cent compared to placebo in non-hospitalized, high-risk adult patients with Covid 19 treated within three days of symptom onset,” the company said in statement.

Within five days from the time symptoms started to manifest, the treatment reduced the risk of hospitalization or death for any cause by 88 per cent compared to placebo, showing an increase from the 85 per cent observed in the interim analysis, Pfizer noted.
The company has submitted the data to the US Food and Drug Administration for emergency use authorization of the treatment.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

BJP to launch campaign focused on young women voters in poll bound states

New Delhi: Ahead of the assembly elections in five states, the Bharatiya Janata Party (BJP) is going to launch...
- Advertisement -

More Articles Like This

- Advertisement -